ASX Life Sciences stocks: Here are 2 of the best!

Marc Kennis Marc Kennis, July 28, 2023

ASX Life Sciences stocks discussed by Stuart Roberts as interest rates peak


What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips on the top Stocks in ASX

When looking at ASX Life Sciences stocks, Stuart points out Neuren Pharmaceuticals (ASX:NEU), saying the company received FDA approval in March for trofinetide and that they are on the verge of developing a new drug. Stuart sees a promising future for the company, foreseeing its potential to become a major pharma firm once investors realise its potential.

He also his view on Botanix Pharmaceuticals (ASX:BOT), another company worth watching due to its potential FDA approval for a drug treating primary axillary hyperhidrosis, a condition affecting 10% of the population. He presents the numerous companies maturing in the life sciences sector, moving beyond approval into the commercialisation stage.

Stuart recommends seeking expert guidance, accessing research, diversifying risk and ensuring only a fraction of your portfolio is exposed to these potentially volatile ASX Life Sciences stocks.


Stuart Roberts talking Life Sciences on AusBiz on 28 July 2023



Stocks Down Under Concierge is here to help you pick winning stocks!

The team at Stocks Down Under have been in the markets since the mid-90s and we have gone through many ups and downs. We have written about every sector, including ASX Life Sciences stocks!

Our Concierge BUY and SELL service picks the best stocks on ASX. We won’t just tell you what to buy – we give you a buy range, price target and stop loss level in order to maximise total returns. And we will only recommend very high conviction stocks where substantial due diligence has been conducted.

Our performance is well ahead of the ASX200 and All Ords.

You can try out Concierge … for FREE.




There’s no credit card needed – the trial expires automatically.



Blog Categories

Recent Posts

share buybacks

Share buybacks: Are they a good sign or a waste of money?

Share buybacks are a controversial topic amongst investors. Some say it is a waste of money, others will welcome it…

AFT Pharmaceuticals

AFT Pharmaceuticals (ASX:AFP): A gem of a dual-listed healthcare company

AFT Pharmaceuticals (ASX:AFP) may not spring to mind as the best company to have come out of New Zealand. Many…

Can Tabcorp’s nеw boss improve the stock’s dwindling odds?

Tabcorp (ASX: TAH) has had a dog of a year, with its share price dropping roughly 40% in the last…